BBA
IPSC icon

Baker Bros. Advisors’s Century Therapeutics IPSC Stock Holding History

Baker Bros. Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-241,684
Closed -$115K – 94
2025
Q1 		$115K Sell
241,684
-555,776
-70% -$418K ﹤0.01% 85
2024
Q4 		$805K Hold
797,460
– – 0.01% 90
2024
Q3 		$1.36M Hold
797,460
– – 0.01% 82
2024
Q2 		$2.03M Hold
797,460
– – 0.03% 80
2024
Q1 		$3.33M Hold
797,460
– – 0.04% 66
2023
Q4 		$2.65M Sell
797,460
-351,880
-31% -$641K 0.03% 69
2023
Q3 		$2.3M Hold
1,149,340
– – 0.01% 83
2023
Q2 		$3.63M Hold
1,149,340
– – 0.02% 82
2023
Q1 		$3.99M Hold
1,149,340
– – 0.02% 75
2022
Q4 		$5.9M Buy
1,149,340
+778,753
+210% +$7.35M 0.04% 75
2022
Q3 		$3.67M Buy
+370,587
New +$3.9M 0.02% 89

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Baker Bros. Advisors's IPSC Position: Q2 2025 in Review

Baker Bros. Advisors sold out of Century Therapeutics (IPSC) in Q2 2025, closing a stake of 241,684 shares — an estimated $115K sold.

Baker Bros. Advisors first reported a position in IPSC in Q3 2022 and held it in 11 quarters. The position peaked at $5.9M in Q4 2022. 65 funds tracked by Wall St. Rank hold IPSC as of Q2 2025.

  • Baker Bros. Advisors reported no remaining Century Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Baker Bros. Advisors sold 241,684 Century Therapeutics shares in Q2 2025, an estimated $115K.
  • Baker Bros. Advisors first reported a position in Century Therapeutics in Q3 2022 and held it in 11 quarters.
  • Baker Bros. Advisors's Century Therapeutics position peaked at $5.9M in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2025.

Based on Baker Bros. Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.